Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 02-May-24 4:16 PM View:  | Mirza Nadeem Q. Chief Medical Officer | Aprea Therapeutics, Inc. (APRE) | 01-May-24 | Grant | 6,730 | -- | -- | 100% 0 to 6.73K | |
| 28-Mar-24 5:57 PM View: | Gilad Oren President, CEO Director | Aprea Therapeutics, Inc. (APRE) | 28-Mar-24 | Grant | 6,725 | -- | -- | 2% 326.57K to 333.3K | |
| 28-Mar-24 5:59 PM View: | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Aprea Therapeutics, Inc. (APRE) | 28-Mar-24 | Grant | 3,365 | -- | -- | 22% 15.5K to 18.87K | |
| 14-Mar-24 8:52 PM View: | Henneman John B III Director | Aprea Therapeutics, Inc. (APRE) | 13-Mar-24 | Purchase | 6,860 | $7.29 | $50,009.40 | 536% 1.28K to 8.14K | |
| 14-Mar-24 8:51 PM View: | Gilad Oren President, CEO Director | Aprea Therapeutics, Inc. (APRE) | 13-Mar-24 | Purchase | 2,000 | $7.29 | $14,580.00 | < 1% 322.77K to 324.77K | |
| 14-Mar-24 8:53 PM View: | Seizinger Bernd R. Director | Aprea Therapeutics, Inc. (APRE) | 13-Mar-24 | Purchase | 6,860 | $7.29 | $50,009.40 | 26% 26.82K to 33.69K | |
| 14-Mar-24 8:54 PM View: | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Aprea Therapeutics, Inc. (APRE) | 13-Mar-24 | Purchase | 1,010 | $7.29 | $7,362.90 | 7% 14.49K to 15.5K | |
| 24-Aug-23 9:50 PM View: | Peters Richard Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-23 | Grant | 500 | -- | -- | 95% 0.53K to 1.03K | |
| 24-Aug-23 9:50 PM View: | Duey Marc Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-23 | Grant | 500 | -- | -- | < 1% 208.98K to 209.48K | |
| 24-Aug-23 9:48 PM View: | Seizinger Bernd R. Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-23 | Grant | 500 | -- | -- | 2% 26.32K to 26.82K | |
| 24-Aug-23 9:51 PM View: | Grissinger Michael Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-23 | Grant | 500 | -- | -- | 167% 0.3K to 0.8K | |
| 24-Aug-23 9:51 PM View: | Henneman John B III Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-23 | Grant | 500 | -- | -- | 64% 0.78K to 1.28K | |
| 24-Aug-23 9:52 PM View: | Pamukcu Rifat Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-23 | Grant | 500 | -- | -- | 3% 16.96K to 17.46K | |
| 08-Jun-23 4:34 PM View: | Seizinger Bernd R. Director | Aprea Therapeutics, Inc. (APRE) | 07-Jun-23 | Purchase | 6,029 | $3.68 | $22,192.10 | 30% 20.3K to 26.32K | |
| 08-Jun-23 4:34 PM View: | Seizinger Bernd R. Director | Aprea Therapeutics, Inc. (APRE) | 06-Jun-23 | Purchase | 4,068 | $3.63 | $14,764.40 | 25% 16.23K to 20.3K | |
| 13-Mar-23 6:30 PM View: | Gilad Oren President, CEO Director | Aprea Therapeutics, Inc. (APRE) | 09-Mar-23 | Grant | 4,000 | -- | -- | 1% 318.77K to 322.77K | |
| 27-Feb-23 6:37 PM View: | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Aprea Therapeutics, Inc. (APRE) | 27-Feb-23 | Grant | 1,000 | $5.25 | $5,250.00 | 7% 13.49K to 14.49K | |
| 30-Jan-23 5:21 PM View: | Hamill John P. SrVP/CFO/Prin. Fin &Acctg. Off | Aprea Therapeutics, Inc. (APRE) | 30-Jan-23 | Grant | 269,879 | -- | -- | 100% 0 to 269.88K | |
| 24-Aug-23 9:50 PM View: | Duey Marc Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-22 | Conversion | 4,009,690 | -- | -- | 2730% 146.89K to 4.16M | |
| 24-Aug-23 9:50 PM View: | Duey Marc Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-22 | Conversion | 11,610 | -- | -- | < 1% 4.16M to 4.17M | |
| 13-Mar-23 6:30 PM View: | Gilad Oren President, CEO Director | Aprea Therapeutics, Inc. (APRE) | 23-Aug-22 | Conversion | 6,045,100 | -- | -- | 1830% 330.31K to 6.38M | |
| 01-Aug-22 5:01 PM View: | Gilad Oren President, CEO | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 101,300 | -- | -- | 44% 229.01K to 330.31K | |
| 01-Aug-22 5:04 PM View: | Korbel Gregory Alan SVP, Chief Operating Officer | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 24,300 | -- | -- | 113% 21.46K to 45.76K | |
| 01-Aug-22 5:06 PM View: | Schade Christian S Director | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 32,400 | -- | -- | 14% 232.85K to 265.25K | |
| 01-Aug-22 5:00 PM View: | Coiante Scott M SVP, Chief Financial Officer | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 60,800 | -- | -- | 72% 84.27K to 145.06K | |
| 01-Aug-22 5:02 PM View: | Grissinger Michael Director | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 5,995 | -- | -- | 100% 0 to 6.0K | |
| 01-Aug-22 5:03 PM View: | Henneman John B III Director | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 5,995 | -- | -- | 62% 9.61K to 15.61K | |
| 01-Aug-22 5:04 PM View: | Pamukcu Rifat Director | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 5,995 | -- | -- | 49% 12.17K to 18.16K | |
| 01-Aug-22 5:05 PM View: | Peters Richard Director | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 5,995 | -- | -- | 130% 4.61K to 10.61K | |
| 01-Aug-22 5:00 PM View: | Duey Marc Director | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 5,995 | -- | -- | 4% 152.34K to 158.34K | |
| 01-Aug-22 5:06 PM View: | Seizinger Bernd R. Director | Aprea Therapeutics, Inc. (APRE) | 28-Jul-22 | Grant | 5,995 | -- | -- | 2% 318.58K to 324.57K | |
| 07-Jun-22 5:02 PM View: | Coiante Scott M SVP, Chief Financial Officer Director | Aprea Therapeutics, Inc. (APRE) | 03-Jun-22 | Payment of Exercise | 35,284 | $0.81 | $28,403.60 | (30%) 119.55K to 84.27K | |
| 07-Jun-22 5:01 PM View: | Korbel Gregory Alan SVP, Chief Operating Officer Director | Aprea Therapeutics, Inc. (APRE) | 03-Jun-22 | Payment of Exercise | 8,390 | $0.81 | $6,753.95 | (28%) 29.85K to 21.46K | |
| 07-Jun-22 5:00 PM View: | Attar Eyal C. SVP, Chief Medical Officer Director | Aprea Therapeutics, Inc. (APRE) | 03-Jun-22 | Payment of Exercise | 32,667 | $0.81 | $26,296.90 | (36%) 90.06K to 57.39K | |
| 07-Jun-22 5:05 PM View: | Schade Christian S Chairman & CEO Director | Aprea Therapeutics, Inc. (APRE) | 03-Jun-22 | Payment of Exercise | 65,770 | $0.81 | $52,944.90 | (22%) 298.62K to 232.85K | |
| 19-May-22 4:30 PM View: | Schade Christian S Chairman & CEO Director | Aprea Therapeutics, Inc. (APRE) | 18-May-22 | Private Purchase | 37,500 | $0.64 | $24,123.80 | 14% 261.12K to 298.62K | |
| 19-May-22 4:31 PM View: | Seizinger Bernd R. Director | Aprea Therapeutics, Inc. (APRE) | 18-May-22 | Private Purchase | 50,000 | $0.71 | $35,500.00 | 19% 268.58K to 318.58K | |
| 14-Mar-22 5:03 PM View: | Schade Christian S Chairman & CEO Director | Aprea Therapeutics, Inc. (APRE) | 10-Mar-22 | Grant | 100,100 | -- | -- | 62% 161.02K to 261.12K | |
| 14-Mar-22 5:03 PM View: | Korbel Gregory Alan SVP, Chief Business Officer Director | Aprea Therapeutics, Inc. (APRE) | 10-Mar-22 | Grant | 16,000 | -- | -- | 101% 15.84K to 31.84K | |
| 14-Mar-22 5:02 PM View: | Coiante Scott M SVP, Chief Financial Officer Director | Aprea Therapeutics, Inc. (APRE) | 10-Mar-22 | Grant | 42,900 | -- | -- | 56% 76.65K to 119.55K | |
| 14-Mar-22 5:03 PM View: | Korbel Gregory Alan SVP, Chief Business Officer Director | Aprea Therapeutics, Inc. (APRE) | 10-Mar-22 | Payment of Exercise | 1,989 | $1.82 | $3,619.98 | (6%) 31.84K to 29.85K | |
| 14-Mar-22 5:01 PM View: | Abrahmsen Lars B. SVP, Chief Scientific Officer | Aprea Therapeutics, Inc. (APRE) | 10-Mar-22 | Grant | 24,700 | -- | -- | 130% 19.0K to 43.7K | |
| 14-Mar-22 5:01 PM View: | Attar Eyal C. SVP, Chief Medical Officer Director | Aprea Therapeutics, Inc. (APRE) | 10-Mar-22 | Grant | 42,900 | -- | -- | 91% 47.16K to 90.06K | |
| 01-Mar-22 5:01 PM View: | Attar Eyal C. SVP, Chief Medical Officer | Aprea Therapeutics, Inc. (APRE) | 28-Feb-22 | Sale (Planned) | 36,000 | $1.73 | $62,280.00 | (43%) 83.33K to 47.33K | |
| 01-Mar-22 5:02 PM View: | Schade Christian S Chairman & CEO Director | Aprea Therapeutics, Inc. (APRE) | 25-Feb-22 | Payment of Exercise | 21,644 | $1.74 | $37,660.60 | (12%) 182.66K to 161.02K | |
| 01-Mar-22 5:01 PM View: | Coiante Scott M SVP, Chief Financial Officer | Aprea Therapeutics, Inc. (APRE) | 25-Feb-22 | Payment of Exercise | 14,817 | $1.74 | $25,781.60 | (16%) 91.47K to 76.65K | |
| 01-Mar-22 5:02 PM View: | Korbel Gregory Alan SVP, Chief Business Officer | Aprea Therapeutics, Inc. (APRE) | 25-Feb-22 | Payment of Exercise | 1,326 | $1.74 | $2,307.24 | (8%) 17.17K to 15.84K | |
| 03-Dec-21 5:01 PM View: | Korbel Gregory Alan SVP, Chief Business Officer | Aprea Therapeutics, Inc. (APRE) | 01-Dec-21 | Market Option Sale (Planned) | 27,500 | $3.96 | $108,900.00 | (62%) 44.67K to 17.17K | |
| 03-Dec-21 5:01 PM View: | Korbel Gregory Alan SVP, Chief Business Officer | Aprea Therapeutics, Inc. (APRE) | 01-Dec-21 | Option Exercise | 27,500 | $0.92 | $25,300.00 | 160% 17.17K to 44.67K | |
| 03-Nov-21 5:34 PM View: | Korbel Gregory Alan SVP, Chief Business Officer | Aprea Therapeutics, Inc. (APRE) | 01-Nov-21 | Market Option Sale (Planned) | 27,500 | $5.00 | $137,500.00 | (62%) 44.67K to 17.17K |
